What is HC Wainwright's Estimate for VERV FY2026 Earnings?

Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report) - Stock analysts at HC Wainwright issued their FY2026 earnings per share (EPS) estimates for Verve Therapeutics in a research note issued to investors on Monday, May 19th. HC Wainwright analyst M. Kapoor anticipates that the company will post earnings per share of ($2.65) for the year. HC Wainwright currently has a "Buy" rating and a $25.00 target price on the stock. The consensus estimate for Verve Therapeutics' current full-year earnings is ($2.49) per share.

Verve Therapeutics (NASDAQ:VERV - Get Free Report) last released its quarterly earnings data on Wednesday, May 14th. The company reported ($0.35) EPS for the quarter, beating analysts' consensus estimates of ($0.71) by $0.36. The business had revenue of $32.98 million for the quarter, compared to the consensus estimate of $7.13 million. Verve Therapeutics had a negative return on equity of 35.23% and a negative net margin of 807.65%.

A number of other brokerages have also recently commented on VERV. Guggenheim lifted their target price on shares of Verve Therapeutics from $18.00 to $24.00 and gave the company a "buy" rating in a report on Tuesday, April 15th. Canaccord Genuity Group boosted their price objective on shares of Verve Therapeutics from $32.00 to $39.00 and gave the stock a "buy" rating in a report on Tuesday, April 15th. Cantor Fitzgerald raised Verve Therapeutics from a "neutral" rating to an "overweight" rating in a research note on Tuesday, April 15th. William Blair reiterated an "outperform" rating on shares of Verve Therapeutics in a report on Friday, February 21st. Finally, Royal Bank of Canada cut their price objective on shares of Verve Therapeutics from $17.00 to $15.00 and set an "outperform" rating for the company in a research report on Tuesday, March 4th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, Verve Therapeutics presently has a consensus rating of "Moderate Buy" and an average price target of $25.75.

Verve Therapeutics Price Performance

Shares of Verve Therapeutics stock traded down $0.02 during trading hours on Tuesday, hitting $4.36. The company had a trading volume of 1,383,381 shares, compared to its average volume of 1,863,624. Verve Therapeutics has a twelve month low of $2.86 and a twelve month high of $9.31. The company has a market cap of $388.66 million, a P/E ratio of -1.77 and a beta of 1.82. The company's 50-day moving average is $4.61 and its two-hundred day moving average is $5.80.

Institutional Investors Weigh In On Verve Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. KFG Wealth Management LLC acquired a new position in shares of Verve Therapeutics in the 1st quarter valued at about $46,000. IFP Advisors Inc lifted its holdings in shares of Verve Therapeutics by 823,700.0% during the 4th quarter. IFP Advisors Inc now owns 8,238 shares of the company's stock valued at $47,000 after acquiring an additional 8,237 shares in the last quarter. Cambridge Investment Research Advisors Inc. purchased a new stake in shares of Verve Therapeutics in the first quarter worth about $47,000. E Fund Management Co. Ltd. acquired a new stake in Verve Therapeutics in the first quarter valued at approximately $48,000. Finally, BNP Paribas Financial Markets purchased a new position in shares of Verve Therapeutics in the fourth quarter valued at $50,000. 97.11% of the stock is currently owned by institutional investors and hedge funds.

About Verve Therapeutics

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.